|
|
|
1-10 employees
View all
|
|
Biotechnology
|
|
San Diego, CA 92122, US
|
|
Around 1.5 billion people around the world suffer from chronic pain, with more than 100 million in the US alone. Conventional treatment for chronic pain consists mostly of opioid narcotics. However, opioids have failed us as the United States is currently undergoing an opioid epidemic. Sadly, over 120 Americans die each day of an opioid overdose.
We have developed a patented, non-permanent gene therapy to target pain that is non-addictive, highly specific and long-lasting. So how does this work? We were inspired by nature: there are humans that have a mutation in their genome that feel no pain whatsoever. We have imitated this process by utilizing a novel gene therapy to target pain in a non-permanent way. In our proof of concept, we have demonstrated that the mice that received our therapy have an increased pain tolerance and lower pain levels. Importantly, mice are not numb and can continue feeling mechanical stimulation, such as touch.
We believe that patients should not have to decide whether they live a life with pain, or one with the risk of addiction.
|
Navega Therapeutics Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Navega Therapeutics email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Navega Therapeutics customer service number in your country click here to find.
Ana Maria Moreno is the CEO of Navega Therapeutics. To contact Ana Maria Moreno email at [email protected], [email protected] or [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.